Acute quetiapine dose-dependently exacerbates anhedonia induced by withdrawal from escalating doses of d-amphetamine

European Neuropsychopharmacology

Volumn 20, Issue 10, 2010, Pages 695-703

  Zhornitsky, Simon ^a   Potvin, Stéphane ^a   Stip, Emmanuel ^a   Rompré, Pierre Paul ^a  

^a CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

Author keywords

Amphetamine; Anhedonia; Dopamine; Quetiapine; Reward; Tolerance

Indexed keywords

DEXAMPHETAMINE; QUETIAPINE;

ANHEDONIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DEPTH STIMULATION; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG MECHANISM; ELECTROSTIMULATION; INSTRUMENTAL CONDITIONING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REWARD; WITHDRAWAL SYNDROME;

EID: 77956170254     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2010.04.011     Document Type: Article

References (61)

1. Barr A.M., Markou A. Psychostimulant withdrawal as an inducing condition in animal models of depression. Neurosci. Biobehav. Rev. 2005, 29:675-706.
2. Barr A.M., Phillips A.G. Withdrawal following repeated exposure to d-amphetamine decreases responding for a sucrose solution as measured by a progressive ratio schedule of reinforcement. Psychopharmacology (Berl) 1999, 141:99-106.
3. Barr A.M., Phillips A.G. Increased successive negative contrast in rats withdrawn from an escalating-dose schedule of d-amphetamine. Pharmacol. Biochem. Behav. 2002, 71:293-299.
4. Benaliouad F., Kapur S., Rompre P.P. Blockade of 5-HT2a receptors reduces haloperidol-induced attenuation of reward. Neuropsychopharmacology 2007, 32:551-561.
5. Benaliouad F., Kapur S., Natesan S., Rompré P.-P. Effects of the dopamine stabilizer, OSU-6162, on brain stimulation reward and on quinpirole-induced changes in reward and locomotion. Eur. Neuropsychopharmacol. 2009, 19:416-430.
6. Bonhomme N., Cador M., Stinus L., Le Moal M., Spampinato U. Short and long-term changes in dopamine and serotonin receptor binding sites in amphetamine-sensitized rats: a quantitative autoradiographic study. Brain Res. 1995, 675:215-223.
7. Boye S.M., Rompre P.-P. Mesencephalic substrate of reward: axonal connections. J. Neurosci. 1996, 16:3511-3520.
8. Brown E.S., Nejtek V.A., Perantie D.C., Rajan Thomas N., Rush A.J. Cocaine and amphetamine use in patients with psychiatric illness: a randomized trial of typical antipsychotic continuation or discontinuation. J. Clin. Psychopharmacol. 2003, 23:384-388.
9. Chambers R.A., Self D.W. Motivational responses to natural and drug rewards in rats with neonatal ventral hippocampal lesions: an animal model of dual diagnosis schizophrenia. Neuropsychopharmacology 2002, 27:889-905.
10. Colle L.M., Wise R.A. Effects of nucleus accumbens amphetamine on lateral hypothalamic brain stimulation reward. Brain Res. 1988, 459:361-368.
11. Cryan J.F., Hoyer D., Markou A. Withdrawal from chronic amphetamine induces depressive-like behavioral effects in rodents. Biol. Psychiatry 2003, 54:49-58.
12. Di Chiara G., Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. USA 1988, 85:5274-5278.
13. Edmonds D.E., Gallistel C.R. Parametric analysis of brain stimulation reward in the rat: III. Effect of performance variables on the reward summation function. J. Comp. Physiol. Psychol. 1974, 87:876-883.
14. Fletcher P.J., Tampakeras M., Yeomans J.S. Median raphe injections of 8-OH-DPAT lower frequency thresholds for lateral hypothalamic self-stimulation. Pharmacol. Biochem. Behav. 1995, 52:65-71.
15. Gallo A., Lapointe S., Stip E., Potvin S., Rompré P.-P. Quetiapine blocks cocaine-induced enhancement of brain stimulation reward. Beh. Brain Res. 2010, 208:163-168.
16. Genn R.F., Barr A.M., Phillips A.G. Effects of amisulpride on consummatory negative contrast. Behav. Pharmacol. 2002, 13:659-662.
17. Haddad P.M., Sharma S.G. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 2007, 21:911-936.
18. Harrison A.A., Markou A. Serotonergic manipulations both potentiate and reduce brain stimulation reward in rats: involvement of serotonin-1A receptors. J. Pharmacol. Exp. Ther. 2001, 297:316-325.
19. Harrison A.A., Liem Y.T., Markou A. Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats. Neuropsychopharmacology 2001, 25:55-71.
20. He J., Xu H., Yang Y., Zhang X., Li X.M. Chronic administration of quetiapine alleviates the anxiety-like behavioural changes induced by a neurotoxic regimen of dl-amphetamine in rats. Behav. Brain Res. 2005, 160:178-187.
21. He J., Yang Y., Yu Y., Li X., Li X.M. The effects of chronic administration of quetiapine on the methamphetamine-induced recognition memory impairment and dopaminergic terminal deficit in rats. Behav. Brain Res. 2006, 172:39-45.
22. Janiri L., Martinotti G., Dario T., Reina D., Paparello F., Pozzi G., Addolorato G., Di Giannantonio M., De Risio S. Anhedonia and substance-related symptoms in detoxified substance-dependent subjects: a correlation study. Neuropsychobiology 2005, 52:37-44.
23. Jensen N.H., Rodriguiz R.M., Caron M.G., Wetsel W.C., Rothman R.B., Roth B.L. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 2008, 33:2303-2312.
24. Kapur S., Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?: a new hypothesis. Am. J. Psychiatry 2001, 158:360-369.
25. Kapur S., Vanderspek S.C., Brownlee B.A., Nobrega J.N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J. Pharmacol. Exp. Ther. 2003, 305:625-631.
26. Karoum F., Chrapusta S.J., Brinjak R., Hitri A., Wyatt R.J. Regional effects of amphetamine, cocaine, nomifensine and GBR 12909 on the dynamics of dopamine release and metabolism in the rat brain. Br. J. Pharmacol. 1994, 113:1391-1399.
27. Kennedy A., Wood A.E., Saxon A.J., Malte C., Harvey M., Jurik J., Kilzieh N., Lofgreen C., Tapp A. Quetiapine for the treatment of cocaine dependence: an open-label trial. J. Clin. Psychopharmacol. 2008, 28:221-224.
28. Kitanaka J., Kitanaka N., Takemura M. Neurochemical consequences of dysphoric state during amphetamine withdrawal in animal models: a review. Neurochem. Res. 2008, 33:204-219.
29. Koob G.F., Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 2001, 24:97-129.
30. Leith N.J., Barrett R.J. Amphetamine and the reward system: evidence for tolerance and post-drug depression. Psychopharmacologia 1976, 46:19-25.
31. Leith N.J., Barrett R.J. Effects of chronic amphetamine or reserpine on self-stimulation responding: animal model of depression?. Psychopharmacology (Berl) 1980, 72:9-15.
32. Lin D., Koob G.F., Markou A. Differential effects of withdrawal from chronic amphetamine or fluoxetine administration on brain stimulation reward in the rat-interactions between the two drugs. Psychopharmacology (Berl) 1999, 145:283-294.
33. Lin D., Koob G.F., Markou A. Time-dependent alterations in ICSS thresholds associated with repeated amphetamine administrations. Pharmacol. Biochem. Behav. 2000, 65:407-417.
34. Martinotti G., Andreoli S., Di Nicola M., Di Giannantonio M., Sarchiapone M., Janiri L. Quetiapine decreases alcohol consumption, craving, and psychiatric symptoms in dually diagnosed alcoholics. Hum. Psychopharmacol. 2008, 23:417-424.
35. Masand P.S., Narasimhan M. Improving adherence to antipsychotic pharmacotherapy. Curr. Clin. Pharmacol. 2006, 1:47-56.
36. Mcintyre R.S., Soczynska J.K., Woldeyohannes H.O., Alsuwaidan M., Konarski J.Z. A preclinical and clinical rationale for quetiapine in mood syndromes. Expert Opin. Pharmacother. 2007, 8:1211-1219.
37. Meltzer H.Y., Matsubara S., Lee J.C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 1989, 251:238-246.
38. Miliaressis E., Rompre P.-P., Laviolette P., Philippe L., Coulombe D. The curve-shift paradigm in self-stimulation. Physiol. Behav. 1986, 37:85-91.
39. Monnelly E.P., Ciraulo D.A., Knapp C., Locastro J., Sepulveda I. Quetiapine for treatment of alcohol dependence. J. Clin. Psychopharmacol. 2004, 24:532-535.
40. Mundl W.J. A constant-current stimulator. Physiol. Behav. 1980, 24:991-993.
41. Newton T.F., Kalechstein A.D., Duran S., Vansluis N., Ling W. Methamphetamine abstinence syndrome: preliminary findings. Am. J. Addict. 2004, 13:248-255.
42. Orsetti M., Canonico P.L., Dellarole A., Colella L., Di Brisco F., Ghi P. Quetiapine prevents anhedonia induced by acute or chronic stress. Neuropsychopharmacology 2007, 32:1783-1790.
43. Paterson N.E., Myers C., Markou A. Effects of repeated withdrawal from continuous amphetamine administration on brain reward function in rats. Psychopharmacology (Berl) 2000, 152:440-446.
44. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1986, Academic Press, New York.
45. Pinkofsky H.B., Hahn A.M., Campbell F.A., Rueda J., Daley D.C., Douaihy A.B. Reduction of opioid-withdrawal symptoms with quetiapine. J. Clin. Psychiatry 2005, 66:1285-1288.
46. Potvin S., Stip E., Lipp O., Elie R., Mancini-Marie A., Demers M.F., Roy M.A., Bouchard R.H., Gendron A. Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial. Curr. Med. Res. Opin. 2006, 22:1277-1285.
47. Rompré P.-P. Psychostimulant-like effect of central microinjection of neurotensin on brain stimulation reward. Peptides 1995, 16:1417-1420.
48. Rossetti Z.L., Hmaidan Y., Gessa G.L. Marked inhibition of mesolimbic dopamine release: a common feature of ethanol, morphine, cocaine and amphetamine abstinence in rats. Eur. J. Pharmacol. 1992, 221:227-234.
49. Ryan L.J., Linder J.C., Martone M.E., Groves P.M. Histological and ultrastructural evidence that d-amphetamine causes degeneration in neostriatum and frontal cortex of rats. Brain Res. 1990, 518:67-77.
50. Sattar S.P., Bhatia S.C., Petty F. Potential benefits of quetiapine in the treatment of substance dependence disorders. J. Psychiatry Neurosci. 2004, 29:452-457.
51. Segal D.S., Kuczenski R. An escalating dose "binge" model of amphetamine psychosis: behavioral and neurochemical characteristics. J. Neurosci. 1997, 17:2551-2566.
52. Semenova S., Markou A. Clozapine treatment attenuated somatic and affective signs of nicotine and amphetamine withdrawal in subsets of rats exhibiting hyposensitivity to the initial effects of clozapine. Biol. Psychiatry 2003, 54:1249-1264.
53. Solomon R.L., Corbit J.D. An opponent-process theory of motivation. I. Temporal dynamics of affect. Psychol. Rev. 1974, 81:119-145.
54. Tarazi F.I., Zhang K., Baldessarini R.J. Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. J. Pharmacol. Exp. Ther. 2001, 297:711-717.
55. Tarazi F.I., Zhang K., Baldessarini R.J. Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions. Psychopharmacology (Berl) 2002, 161:263-270.
56. Teran A., Majadas S., Galan J. Quetiapine in the treatment of sleep disturbances associated with addictive conditions: a retrospective study. Subst. Use Misuse 2008, 43:2169-2171.
57. Wadenberg M.L., Soliman A., VanderSpek S.C., Kapur S. Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 2001, 25:633-641.
58. White F.J., Kalivas P.W. Neuroadaptations involved in amphetamine and cocaine addiction. Drug Alcohol Depen. 1998, 51:141-153.
59. Wise R.A. Addictive drugs and brain stimulation reward. Annu. Rev. Neurosci. 1996, 19:319-340.
60. Wise R.A., Munn E. Effects of repeated amphetamine injections on lateral hypothalamic brain stimulation reward and subsequent locomotion. Behav. Brain Res. 1993, 55:195-201.
61. Wise R.A., Rompre P.P. Brain dopamine and reward. Annu. Rev. Psychol. 1989, 40:191-225.